Institute for Life Science Entrepreneurship supports startups and entrepreneurs in the life sciences sector with research, development, and business support. It is self-described as a 501(c)(3) not-for-profit organization.

Institute for Life Science Entrepreneurship

Institute For Life Science Entrepreneurship (ILSE) | 833 followers on LinkedIn. ILSE is a research institute, accelerator and incubator facilitating translation of early innovation into successful Tx. | The Institute for Life Science Entrepreneurship (ILSE) is a newly formed organization structured to become a uniquely effective model for academic, industry, and entrepreneurial collaboration.  The Institute&#39;s mission is to catalyze and accelerate the translation of breakthrough discoveries in the life sciences into safe and effective pharmaceutical, biological, medical device and biotechnology products.  It has been designed to link together time-critical resources on a large scale from a broad spectrum of disciplines and players in academia and industry to advance innovation, creativity and entrepreneurism (ICE) in the life sciences.

Keith Bostian

President at Institute For Life Science Entrepreneurship (ILSE) Founder and CEO, Plumeria Therapeutics, Inc.

Thomas P. Richardson PhD, MBA

Chairman of Advisory Council at Institute of Life Science Entrepreneurship

Rashmi Barbhaiya

Senior Vice President, Head of Real-World Data Product Strategy

Bill Hanlon

Institute For Life Science Entrepreneurship (ILSE)

CARB-X 2024 Funding Round The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced funding solicitation with four distinct product themes: THERAPEUTICS FOR INFECTIONS CAUSED BY GRAM-NEGATIVE PATHOGENS The scope is restricted to direct-acting small-molecule therapeutics. Molecules with properties that will deliver an IV route with an oral stepdown are preferred. In all cases, activity against both susceptible and multidrug-resistant organisms on the WHO and CDC bacterial threat lists is essential. PREVENTION FOR INVASIVE DISEASE Novel approaches to prevention of invasive disease caused by Staphylococcus aureus or Escherichia coli are sought. Given the history of challenges in drug development in this arena, modalities other than vaccines are preferred; however, if a vaccine is proposed, a novel aspect (e.g. adjuvant strategy or vaccine composition) that makes a compelling case must be underscored. DIAGNOSTICS FOR NEONATAL SEPSIS Consistent with CARB-X “Aligned by Design” strategy, they seek diagnostics to support the growing portfolio of potential maternal vaccines to prevent neonatal sepsis. Products focused on rapid triage, bacterial identification and/or automated susceptibility testing are sought. Time-to-result and cost-of-goods are key criteria, and small-sample volumes are critical for this patient population. Pathogen ID and AST Products must focus on priority pathogens, including Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus and Acinetobacter baumannii. PROOF-OF-CONCEPT FOR NOVEL SAMPLE TYPES FOR DIAGNOSING LOWER-RESPIRATORY-TRACT INFECTIONS Consistent with our “Aligned by Design” strategy, we seek diagnostics to support the many therapeutic projects focused on lower-respiratory-tract infections (LRTI). Owing to the challenges with BAL samples, as a first step, projects that can demonstrate proof-of-concept data with novel sample types are sought. Target product profiles and minimal acceptable criteria for all funding calls will be defined and available on carb-x.org . Expressions of interest for all themes may be submitted during these timeframes: 18 March 2024 at 10:00 ET – 29 March 2024 at 23:59 ET 23 September 2024 at 10:00 ET – 4 October 2024 at 23:59 ET Further details are available at CARB-X.org website

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 12, 2024 8:24 AM	56fe903a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 12, 2024 8:24 AM	ede493f8
crunchbase trigger	general	Nov 12, 2024 8:24 AM	e5fcc325
crunchbase profile	general
li profile	general	Nov 12, 2024 8:24 AM	d3c9f5db
translate crunchbase fundingrounds	general
peers	general	Nov 12, 2024 8:24 AM	304f16d6
news basic	general	Nov 12, 2024 8:24 AM	91aa8363
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ILSE

COM:ILSEBIO

Institute for Life Science Entrepreneurship